So to my knowledge, there are some ongoing trials looking at newer generations of BRAF and MEK inhibitors that may be more brain penetrant, right, based on pre-clinical data. So I think it’ll be exciting to see results as they become available from those newer BRAF and MEK inhibitors to see if they are therapeutically more effective than the current generation of BRAF-MEK inhibitors that are available...
So to my knowledge, there are some ongoing trials looking at newer generations of BRAF and MEK inhibitors that may be more brain penetrant, right, based on pre-clinical data. So I think it’ll be exciting to see results as they become available from those newer BRAF and MEK inhibitors to see if they are therapeutically more effective than the current generation of BRAF-MEK inhibitors that are available. And then I think with immunotherapy drugs, traditionally they’re delivered intravenous or subcutaneous, but there’s also been trials looking at, for example, intrathecal delivery of immunotherapy drugs. Right now, those have been limited to patients with leptomeningeal disease. But I think with newer combinations of those delivery methods and more brain-penetrant versions of targeted therapy drugs. Our hope is that as the field moves forward, we’ll be able to improve outcomes in patients with symptomatic melanoma brain metastases.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
